Organoids have emerged as transformative tools in cancer research due to their ability to mimic the three-dimensional architecture and cellular complexity of human tumors more accurately than conventional two-dimensional cell cultures. Despite their biological fidelity, scaling organoid production and analysis while maintaining consistency and speed has remained elusive. The newly developed platform addresses these limitations by integrating extrusion bioprinting, which fabricates uniform tumor organoids embedded within extracellular matrix constructs tailored for multiwell plate formats. This advancement ensures high-throughput generation of physiologically relevant tumor models suitable for comprehensive drug screening.

One of the defining features of this platform is its reliance on label-free quantitative phase imaging, a high-speed optical technique that captures intrinsic properties of living cells without the need for fluorescent or chemical dyes. This allows continuous, non-invasive monitoring of organoid biomass changes and growth dynamics over extended periods, providing vital insights into tumor fitness and treatment-induced alterations. The avoidance of staining protocols circumvents the potential perturbations and temporal limitations associated with traditional destructive assays, thereby enabling more accurate longitudinal studies of tumor response.

To handle the enormous volumes of complex imaging data generated during these monitoring sessions, the researchers incorporated advanced computational methodologies, including automated image reconstruction and deep learning-based segmentation. This enables precise delineation of individual organoids and their morphological features across thousands of samples. Subsequently, machine learning algorithms track the temporal evolution of each organoid’s response to diverse drug treatments, quantifying heterogeneity within tumor populations and unmasking subtle differences that could dictate therapeutic efficacy or resistance.

This comprehensive analytical framework was rigorously validated using both established cancer cell lines and patient-derived tumor samples, successfully capturing dynamic responses to a variety of clinically relevant chemotherapeutic compounds. By transcending the traditional bulk average responses, the system pinpoints discrete organoid subsets exhibiting sensitivity or resistance, thereby refining the resolution of drug response assessments. This granular perspective facilitates the identification of rare, treatment-refractory tumor cell populations which are often responsible for therapeutic failure and disease relapse.

Dr. Michael Teitell, the director of the UCLA Health Jonsson Comprehensive Cancer Center and a co-senior author of the study, emphasized the platform’s transformative potential. He highlighted how this technology allows researchers to move beyond averaged drug efficacy metrics, instead illuminating the heterogeneous landscape of tumor cell drug responses at a single-organoid level. This capability to dissect tumor complexity lays the groundwork for unraveling underlying biological mechanisms governing differential treatment responses, which can guide the development of more targeted and effective therapeutic strategies.

Integral to this study is the platform’s capability to generate high-quality datasets amenable to large-scale analysis. By leveraging artificial intelligence, the system can process and interpret multifaceted phenotypic data, thus enabling simultaneous screening of hundreds of drug candidates. This scalability accelerates the pace of drug discovery by swiftly identifying promising therapeutic agents and combinations, particularly for cancers that currently lack robust treatment options. The ability to evaluate organoid responses in a high-throughput manner heralds a significant leap forward for translational oncology research.

Beyond its research applications, the platform holds tremendous promise for clinical oncology. When applied to patient-derived tumor cells, it offers a novel avenue for personalized treatment planning by preemptively testing the efficacy of various drugs on a patient’s own tumor organoids prior to therapy initiation. This approach could minimize the uncertainty inherent in current cancer treatment regimens and reduce exposure to ineffective therapies, thereby enhancing patient outcomes and quality of life — especially for those afflicted with rare or treatment-resistant malignancies.

The incorporation of advanced automated imaging and AI-powered analytical tools in this platform addresses several critical barriers that have historically impeded the integration of organoid models into clinical decision-making. Key among these are the challenges of maintaining biological accuracy while achieving experimental throughput and real-time data acquisition. By harmonizing these factors, the research team has crafted a versatile and robust workflow that is not only poised to revolutionize laboratory investigations but also to inform precision medicine initiatives.

The collaborative nature of this research extends beyond UCLA, with contributions from experts at institutions such as the University of Colorado School of Medicine and Virginia Commonwealth University’s Massey Comprehensive Cancer Center. The multidisciplinary team, combining expertise in pathology, laboratory medicine, bioengineering, and computational sciences, exemplifies the integrative approach necessary to tackle the complexity of cancer biology and translate technological advances into tangible clinical benefits.

Financial support for this pioneering work came from several prestigious entities including the Air Force Office of Scientific Research, the U.S. Department of Defense, the National Science Foundation, and the National Institutes of Health. Such diverse funding underscores the broader recognition of the importance of advanced technological platforms that integrate biology with AI to combat cancer, one of the most formidable health challenges globally.

In summary, this innovative platform heralds a new era in cancer research and treatment by providing an unparalleled toolset to observe, quantify, and predict tumor responses to therapy with extraordinary precision and scale. It embodies a fusion of 3D bioprinting, sophisticated label-free imaging, and artificial intelligence, collectively empowering researchers and clinicians to unravel tumor heterogeneity, uncover mechanisms of drug resistance, and ultimately refine personalized treatment strategies for patients facing challenging cancer diagnoses.

Subject of Research: Development of an integrated 3D bioprinting and AI-based platform for monitoring cancer tumor organoid responses to therapy.

Article Title: Not specified in the provided content.

News Publication Date: Not specified in the provided content.

Web References:
– UCLA Health Jonsson Comprehensive Cancer Center: https://www.uclahealth.org/cancer
– Nature Protocols article: https://www.nature.com/articles/s41596-026-01375-5

References:
Wang, B., Tebon, P., Nguyen, T., Sartini, S., Murray, G., Guest, D., Reed, J., Soragni, A., & Teitell, M. (2026). [Article Title]. Nature Protocols. DOI: 10.1038/s41596-026-01375-5.

Image Credits: Not provided.

Keywords: Organoids, Cancer, Cancer research, 3D bioprinting, Quantitative phase imaging, Artificial intelligence, Tumor heterogeneity, Personalized medicine, Drug screening, High-throughput screening.

Human kidney organoids, miniature three-dimensional structures derived from pluripotent stem cells, mimic many key elements of kidney architecture and function, though they do not constitute fully developed organs. These organoids serve as invaluable models for understanding kidney development, enabling drug screening, disease modeling, and potentially providing a cellular therapy option to regenerate or repair damaged renal tissue. The primary challenge that has limited clinical translation until now has been the difficulty of generating kidney organoids in a scalable, consistent, and economically feasible manner.

The research team, led by Dr. Núria Montserrat, who has transitioned into her role as Catalonia’s Minister of Research and Universities, has developed a robust, systematic protocol that achieves mass production of thousands of kidney organoids using advanced microaggregation techniques combined with precise genetic engineering tools. This method allows for highly uniform organoid generation in a controlled laboratory environment within a significantly shortened timeframe, bypassing the requirement for complex reagents or components that typically inflate research costs.

One of the most innovative aspects of this study lies in the integration of human kidney organoids into living porcine kidneys maintained on normothermic machine perfusion devices. These organ support machines, commonly used in clinical transplantation, preserve organs ex vivo by delivering oxygenated blood at physiological temperatures, thereby enabling real-time organ function monitoring. By harnessing this technology, the team successfully implanted the organoids into the pig kidneys and observed their survival, integration, and functional stability over 24 to 48 hours both ex vivo and in vivo within the same animal model.

Machine perfusion permits continuous assessment of physiological parameters, such as renal filtration and tissue oxygenation, offering unprecedented insight into the viability and potential immune rejection of the implanted organoids. Remarkably, the human cells remained viable and engrafted without eliciting notable immune responses or signs of cytotoxicity. The transplanted porcine kidneys maintained functional integrity, highlighting the potential compatibility of cross-species organoid transplantation under controlled conditions.

This breakthrough approach outlines a visionary pathway toward organ regeneration prior to transplantation, wherein donor kidneys could be preconditioned and treated with human stem-cell-derived organoids to repair or enhance function before surgical implantation. Such capability could substantially improve transplant outcomes, reduce waiting times for transplant candidates, and alleviate the chronic shortage of viable donor organs. The translational nature of this work was bolstered by close collaboration with key clinical and research institutions, including Spain’s National Transplant Organisation and multiple biomedical research centers.

The methodological innovation hinges on the capability to produce large quantities of standardized organoids, overcoming one of the most significant bottlenecks in regenerative nephrology. By utilizing microaggregation and genetic editing platforms, the researchers optimized differentiation processes to yield reproducible kidney-specific cell types within the organoids, including renal tubules and podocytes—essential components for normal kidney function. Immunofluorescence imaging confirmed the spatial organization of these cells, demonstrating clear markers such as LTL, WT1, PODXL, and DAPI indicative of the organoids’ sophisticated cellular architecture.

Such high-throughput organoid generation coupled with real-time evaluation during ex vivo perfusion represents a quantum leap in tissue engineering. It unlocks the potential for precision medicine applications where individual patient-derived cells could be expanded and tested rapidly, facilitating personalized drug screening regimes or therapeutic interventions tailored to specific nephropathies or renal failure conditions. The scalability and efficiency of this system set a new benchmark for laboratory-to-clinic translation in bioengineering.

In addition to its biomedical implications, the study also emphasizes the critical role of interdisciplinary collaboration. Teams spanning bioengineering, transplant surgery, immunology, and stem cell biology from institutions across Europe and the United States jointly contributed to this research, highlighting a truly global effort to tackle complex challenges in organ regeneration. The involvement of medical technology companies specializing in organ perfusion devices underlines the alliance between academic research and industry innovation.

Looking forward, the research group aims to extend the window of organoid survival post-transplantation and explore the potential for full functional maturation within xenogeneic settings, ultimately aiming for clinical trials in human patients. Further research into immune modulation and vascular integration will be essential to achieve long-term stability and functionality of transformed organs. The promise of combining ex vivo regenerative techniques with advanced machine perfusion may redefine transplant medicine paradigms.

This groundbreaking publication, entitled “Systematic production of human kidney organoids for transplantation in porcine kidneys during ex vivo machine perfusion,” was recently featured in Nature Biomedical Engineering. It underscores a decade-long scientific journey driven by relentless pursuit of innovation to make regenerative therapies a clinical reality, highlighting how state-of-the-art bioengineering can synergize with clinical transplantation to save lives. The study’s interdisciplinary nature, scalability, and translational potential mark it as a seminal contribution poised to generate significant impact in medicine and organ bioengineering worldwide.

The Institute for Bioengineering of Catalonia, a leading center recognized for excellence in multidisciplinary bioengineering and life sciences research, continues to break ground in the field of organoid technology and tissue engineering. Their work exemplifies how strategic collaboration between universities, governmental agencies, and industry partners can accelerate revolutionary innovations, bridging the gap from bench to bedside in a socially impactful manner.

Subject of Research: Animals
Article Title: Systematic production of human kidney organoids for transplantation in porcine kidneys during ex vivo machine perfusion
News Publication Date: 31-Oct-2025
Web References: https://www.nature.com/articles/s41551-025-01542-1
References: Elena Garreta et al., Nature Biomedical Engineering (2025), DOI: 10.1038/s41551-025-01542-1
Image Credits: Institute for Bioengineering of Catalonia
Keywords: Organoids, Stem cells, CRISPRs, Medical technology, Regenerative medicine, Tissue engineering, Biomedical engineering, Nephropathies, Renal failure, Kidney